Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 326

Similar articles for PubMed (Select 17597712)

1.

The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.

Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, King TM, Delahunty T, Bushman LR, Fletcher CV.

Clin Pharmacol Ther. 2008 Feb;83(2):265-72. Epub 2007 Jun 27.

PMID:
17597712
2.

Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients.

Kiser JJ, Aquilante CL, Anderson PL, King TM, Carten ML, Fletcher CV.

J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):298-303.

PMID:
18398970
3.

Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir.

Gérard L, Chazallon C, Taburet AM, Girard PM, Aboulker JP, Piketty C.

Antivir Ther. 2007;12(1):31-9.

PMID:
17503745
4.

Lack of evidence for an effect of lopinavir/ritonavir on tenofovir renal clearance.

Ray AS, Wright MR, Rhodes GR.

Clin Pharmacol Ther. 2008 Dec;84(6):660; author reply 661. doi: 10.1038/clpt.2008.140. Epub 2008 Jul 9. No abstract available.

PMID:
18615003
5.

Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.

Pruvost A, Negredo E, Théodoro F, Puig J, Levi M, Ayen R, Grassi J, Clotet B.

Antimicrob Agents Chemother. 2009 May;53(5):1937-43. doi: 10.1128/AAC.01064-08. Epub 2009 Mar 9.

6.

Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.

von Hentig N, Dauer B, Haberl A, Klauke S, Lutz T, Staszewski S, Harder S.

Eur J Clin Pharmacol. 2007 Oct;63(10):935-40. Epub 2007 Jul 31.

PMID:
17665183
7.

Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors.

Cihlar T, Ray AS, Laflamme G, Vela JE, Tong L, Fuller MD, Roy A, Rhodes GR.

Antivir Ther. 2007;12(2):267-72.

PMID:
17503669
8.

Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective study.

Huang F, Scholl P, Huang DB, MacGregor TR, Taub ME, Vinisko R, Castles MA, Robinson P.

Basic Clin Pharmacol Toxicol. 2011 Mar;108(3):163-70. doi: 10.1111/j.1742-7843.2010.00636.x. Epub 2010 Oct 27.

PMID:
20977679
9.

Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir.

Kearney BP, Mathias A, Mittan A, Sayre J, Ebrahimi R, Cheng AK.

J Acquir Immune Defic Syndr. 2006 Nov 1;43(3):278-83.

PMID:
17079992
10.

The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients.

Kruse G, Esser S, Stocker H, Breske A, Koerber A, Kopperman M, Wiehler H, Ross B, Möcklinghoff C, Hill A, Becker M, Kurowski M.

Antivir Ther. 2005;10(2):349-55.

PMID:
15865230
11.

An open-label pilot study to determine the efficacy of lopinavir/ritonavir and tenofovir DF in the treatment of HIV-infected patients experiencing first virologic failure on a non-nucleoside-based regimen.

Pierone G Jr, Mieras J, Bulgin-Coleman D, Kantor C, Shearer J, Fontaine L, Fath M.

AIDS Patient Care STDS. 2008 Apr;22(4):263-6. doi: 10.1089/apc.2007.0148. No abstract available.

PMID:
18422459
12.

Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.

Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR, Harris DR, Havens PL; Adolescent Trials Network for HIV/AIDS Interventions.

Antimicrob Agents Chemother. 2008 Feb;52(2):631-7. Epub 2007 Nov 19.

13.

Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.

Palacios R, Hidalgo C, Ríos MJ, Rivero A, Muñoz L, Lozano F, Gutiérrez-Ravé V, Gálvez MC, del Arco A, Santos J.

Eur J Clin Microbiol Infect Dis. 2009 Apr;28(4):399-402. doi: 10.1007/s10096-008-0636-x. Epub 2008 Oct 8.

PMID:
18841401
14.

Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir.

Kurowski M, Walli RK, Breske A, Kruse G, Stocker H, Banik N, Richter H, Mazur D.

AIDS. 2007 Jun 19;21(10):1368-70.

PMID:
17545717
15.

Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.

Luber AD, Condoluci DV, Slowinski PD, Andrews M, Olson K, Peloquin CA, Pappa KA, Pakes GE; COL104422 Study Team.

HIV Med. 2010 Mar;11(3):193-9. doi: 10.1111/j.1468-1293.2009.00765.x. Epub 2009 Oct 23.

PMID:
19863619
16.

Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.

Waters LJ, Moyle G, Bonora S, D'Avolio A, Else L, Mandalia S, Pozniak A, Nelson M, Gazzard B, Back D, Boffito M.

Antivir Ther. 2007;12(5):825-30.

PMID:
17713166
17.
18.

[Tenofovir: pharmacology and interactions].

Azanza JR, García Quetglas E, Sádaba B, Gómez-Giu A.

Enferm Infecc Microbiol Clin. 2008 Jun;26 Suppl 8:2-6. Review. Spanish.

PMID:
19195431
19.

Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy.

Côté HC, Magil AB, Harris M, Scarth BJ, Gadawski I, Wang N, Yu E, Yip B, Zalunardo N, Werb R, Hogg R, Harrigan PR, Montaner JS.

Antivir Ther. 2006;11(1):79-86.

PMID:
16518963
20.

Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors.

Robbins BL, Capparelli EV, Chadwick EG, Yogev R, Serchuck L, Worrell C, Smith ME, Alvero C, Fenton T, Heckman B, Pelton SI, Aldrovandi G, Borkowsky W, Rodman J, Havens PL; PACTG 1038 Team.

Antimicrob Agents Chemother. 2008 Sep;52(9):3276-83. doi: 10.1128/AAC.00224-08. Epub 2008 Jul 14.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk